The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
GE arrives to the spin-out party fashionably late.
J&J sells another unit.